Data from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma

<div>Abstract<p>Altered lipid metabolism is a common hallmark of various cancers, including intrahepatic cholangiocarcinoma (ICC), a highly lethal carcinoma that lacks effective treatment options. To elucidate the lipid metabolism changes in ICC, we coupled the expression of the firefly luciferase gene (FFL) to <i>AKT1</i> (<i>AKT-FFL</i>) via an IRES linker, and then hydrodynamically injected mice with AKT-FFL and <i>Notch1</i> intracellular cytoplasmic domain (<i>NICD</i>) to establish a luciferase-positive ICC model. This model not only enabled us to monitor and quantify tumor growth by injecting the mice with luciferin, but also allowed us to assess the fatty acid uptake rate by injecting the mice with free fatty acid luciferin (FFA-Luc). The ICC model exhibited robust uptake of exogenous fatty acids compared with the HCC model induced by AKT-FFL/ neuroblastoma <i>Ras</i> (<i>Ras</i>). Lipidomics analysis showed a dramatically higher level of fatty acid in ICC, further supporting the increased fatty acids uptake. Mechanistic studies identified FATP5 as the predominant mediator of fatty acid uptake required for ICC growth using <i>Fatp5</i> knockout mice and AAV-based shRNA silencing of <i>Fatp5</i>. Our study discovered a novel therapeutic target for the treatment of ICC and shed light on the contributions of lipid metabolism to ICC development.</p>Implications:<p>This study provides the first <i>in vivo</i> evidence that FATP5 is a potential therapeutic target for treating ICC.</p></div>